Octapharma is a privately held global human protein manufacturer based in Lachen, Switzerland. Since its establishment in 1983, the company has been dedicated to improving patients’ lives. Octapharma’s commitment to patient care has begun since its inception. We have a history of establishment of benchmarks for product and patient safety, the first manufacturer to apply the solvent inactivation solvent / detergent (S / D) process to production. We are committed to the development of innovative products that help in improving the patient’s quality of life.
Contact:
Address: Av. Ayrton Senna 1.850, Lj. 118 CEP 22775-003, Rio de Janeiro, Brazil
Tel.: +55 21 24303183
Website: www.octapharma.com
Email: octapharma@octapharma.com
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
Mr. Mauricio, you’ve mentioned that Brazil is a different kind of market for Octapharma, one strongly based on price, and that because of this it’s hard to add value. Could…
Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy…
Laurena de Almeida Magnoni, regional director for Latin America at Besins Healthcare, a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for men’s…
Norberto Prestes, director of the Brazilian Pharmochemicals Manufacturers Association (ABIQUIFI), provides insights into the main dynamics that have been shaping Brazil’s pharmaceutical and API sectors over the past few years,…
Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land…
Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he…
Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the…
Dr. Ogari Pacheco, president of the Board of Directors for Cristália, highlights the unique journey for Cristália over the past 45 years, as one of the most innovative local pharma…
Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for…
Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international…
Heraldo Marchezini, CEO of the Brazilian biotech company Biomm and one of the leading executives in the Brazilian biopharmaceutical sector, provides insights into the eye-catching international partnerships recently signed by…
Marco Fireman, vice-minister and chairman of the National Commission for the Incorporation of Technologies (CONITEC); a board that advises the Brazilian Ministry of Health on the inclusion of new health…
Samuel Mauricio, vice-president for Brazil at Octapharma, one of the largest human protein manufacturers in the world, provides an insightful analysis of the Brazilian plasma market, demonstrating Octapharma’s remarkable willingness…
See our Cookie Privacy Policy Here
